cancer-immunotherapy | Media Room

Press Release Dec 12, 2024

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Two of three patients achieved both complete remission and MRD-negative status

High response rates observed in earlier studies continue in ongoing mipletamig trial

Cohort 2 enrollment commencing

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform" at Cambridge Healthcare Institute's, Pep Talk 2025

BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies

After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers. Read More

Press Release Aug 2, 2019

Tumor-Specific Antigen Market to See 6.2% Annual Growth Through 2023

Growing Prevalence of Cancer and Increasing Investment in Research Driving Expansion Read More

Press Release Apr 11, 2016

Dr. Jamal Khan's Cancer Immunotherapy Makes a Mark

A work pioneered by Dr. Khan in India over a decade and his efforts have been widely hailed today in a glittering ceremony at Delhi where he was decorated with innovators award organized by Optimal Media Solutions. Read More